Fort Worth, TX — Crestline Investors, Inc. (“Crestline”), alongside Noro-Moseley Partners and Echo Health Ventures, announces the closing of a senior secured credit facility to Medix Infusion (“Medix”), a leading provider of ambulatory infusion and specialty pharmacy services for patients with chronic and advanced conditions. The proceeds will support the company’s sustained growth and operational needs.
“We’re excited to support the Medix team along with its investor group. As a leading multi-state infusion provider, Medix has built a scaled platform serving providers and patients with essential infusion services in what we believe is a growing and attractive market,” said Marc Strauss, Senior Managing Director at Crestline. “We also feel fortunate to be able to work with two highly respected healthcare investors, who provide critical support to the continued advancement of Medix’s specialized capabilities in serving their patients.”
“We’re equally pleased to partner with the Crestline team, whose flexibility and financing capacity were critical in bringing this transaction together,” said Ryan Collins, Principal at Noro-Moseley Partners. “Their ability to provide flexible capital that allows Medix to continue to scale is very important for Medix’s continued successful operational execution.”
About Crestline Investors, Inc.
Crestline Investors, Inc. is an alternative investment management firm founded in 1997 and based in Fort Worth, Texas, with affiliate offices in London, New York, Toronto, and Tokyo. The firm has approximately $16 billion in assets under management (as of December 31, 2024), and is specialized in private credit strategies, offering a diverse range of investment solutions across its direct lending, opportunistic, and portfolio finance platforms. For more information, visit www.crestlineinvestors.com.
About Medix Infusion
Headquartered in Addison, TX, Medix Infusion provides ambulatory infusion therapy and specialty pharmacy services across seven states through more than 50 clinics and pharmacies. The company serves patients with chronic and high-acuity conditions via a vertically integrated care model that includes in-clinic, home-based, and pharmacy services. For more information, visit www.medixinfusion.com.
About Noro-Moseley Partners
Established in 1983, Noro-Moseley Partners is a venture capital firm focused on partnering with exceptional entrepreneurs in the healthcare and information technology sectors. With over 70 years of collective investing experience, the firm brings deep domain expertise, strategic relationships, and a long track record of supporting high-growth companies across key innovation hubs in the U.S. For more information, visit www.noromoseley.com.
About Echo Health Ventures
Founded in 2016, Echo Health Ventures is a strategic venture capital and growth equity firm focused on advancing healthcare transformation nationwide. The Echo Innovation Alliance, backed by Cambia Health Solutions, CuraCor Solutions, USAble Corporation and BlueCross BlueShield of Tennessee, supports innovative companies with long-term capital and industry expertise to help scale impactful healthcare solutions. For more information, visit www.echohealthventures.com.
This financial promotion is issued by Crestline Management, LP and Crestline Europe, LLP (together "Crestline"). Crestline Europe, LLP is authorized and regulated by the Financial Conduct Authority (FCA). The material is not intended to be a formal research report and nothing in this presentation should be interpreted to state or imply that past results are an indication of future performance. Any opinions expressed herein are our current opinions only. There can be no assurance or guarantee that Crestline's investment strategy will achieve its stated goal. All information provided in this presentation is for informational purposes only Crestline accepts no liability for loss arising from the use of this material. In the United Kingdom, this communication is being made only to, or directed only at, persons who are: (i) investment professionals within the meaning of Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“FP Order”); (ii) high net worth companies and certain other entities falling within Article 49 of the FP Order; or (iii) any other persons to whom such communication may lawfully be made. It must not be acted, or relied, upon by any other persons.
